We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.45B
AUM Growth
-$251M
Cap. Flow
-$193M
Cap. Flow %
-7.88%
Top 10 Hldgs %
50.47%
Holding
123
New
19
Increased
24
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.2M
2
GOSS icon
Gossamer Bio
GOSS
+$34.6M
3
XLRN
Acceleron Pharma
XLRN
+$26.3M
4
EPZM
Epizyme, Inc
EPZM
+$19.6M
5
BPMC
Blueprint Medicines
BPMC
+$18.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$10.4M
2
BLUE
bluebird bio
BLUE
+$10.2M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10M
4
ANAB icon
AnaptysBio
ANAB
+$9.57M
5
ARGX icon
argenx
ARGX
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 63.96%
2 Consumer Discretionary 16.48%
3 Technology 3.08%
4 Real Estate 0.36%
5 Communication Services 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
101
Ironwood Pharmaceuticals
IRWD
$604M
$1.25M 0.05%
131,975
– –
CMRX
102
DELISTED
Chimerix, Inc.
CMRX
$1.05M 0.04%
500,000
-500,000
-50% -$1.14M
NVLN
103
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$315K 0.01%
256,400
– –
TRIL
104
DELISTED
Trillium Therapeutics Inc.
TRIL
$99K ﹤0.01%
150,000
– –
ALNY icon
105
CALL
Alnylam Pharmaceuticals
ALNY
$38.6B
– –
-300,000
Closed -$21.9M
ANAB icon
106
AnaptysBio
ANAB
$1.52B
– –
-150,000
Closed -$9.57M
BLUE
107
CALL
DELISTED
bluebird bio
BLUE
– –
-7,720
Closed -$9.92M
BMRN icon
108
CALL
BioMarin Pharmaceuticals
BMRN
$12B
– –
-200,000
Closed -$17M
FCX icon
109
CALL
Freeport-McMoran
FCX
$84.9B
– –
-2,000,000
Closed -$20.6M
KYNB
110
CALL
Kyntra Bio
KYNB
$28.2M
– –
-6,000
Closed -$6.94M
MS icon
111
CALL
Morgan Stanley
MS
$323B
– –
-1,500,000
Closed -$59.5M
MU icon
112
CALL
Micron Technology
MU
$884B
– –
-400,000
Closed -$12.7M
VALE icon
113
CALL
Vale
VALE
$62.1B
– –
-500,000
Closed -$6.59M
WFC icon
114
CALL
Wells Fargo
WFC
$259B
– –
-1,500,000
Closed -$69.1M
WYNN icon
115
CALL
Wynn Resorts
WYNN
$10.2B
– –
-100,000
Closed -$9.89M
YMAB
116
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-50,000
Closed -$1.02M
QTTB icon
117
Q32 Bio
QTTB
$457M
– –
-5,556
Closed -$2.24M
ONC
118
CALL
BeOne Medicines Ltd
ONC
$34B
– –
-200,000
Closed -$28.1M
MRNS
119
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-125,000
Closed -$1.44M
CLVS
120
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-200,000
Closed -$3.59M
MNTA
121
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-200,000
Closed -$2.21M
MDCO
122
CALL
DELISTED
Medicines Co
MDCO
– –
-600,000
Closed -$11.5M
CMTA
123
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-850,000
Closed -$10M
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2019 Portfolio in Review

As of Q1 2019, Artal Group held 123 positions worth $2.45B, down 9.3% from $2.7B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group withdrew a net $193M in Q1 2019, closing 19 positions and reducing 18 holdings. Its most notable exit was Clementia Pharmaceuticals Inc., an estimated $10M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in NVIDIA worth $75.4M.

  • Artal Group's largest Q1 2019 buy was NVIDIA: 16,800,000 shares worth $75.4M.
  • Artal Group added most to Acceleron Pharma in Q1 2019, an estimated $26.3M increase.
  • Artal Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $10.4M.
  • Artal Group fully exited Clementia Pharmaceuticals Inc. in Q1 2019, selling an estimated $10M.
  • Artal Group's ten largest holdings make up 50% of its $2.45B portfolio in Q1 2019.
  • Artal Group opened 19 new positions and closed 19 in Q1 2019.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $2.45B.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.